ECMO支持脑死亡供者的器官利用与结局:两中心经验
该两中心回顾性队列纳入2012年1月至2025年6月210例脑死亡供者,其中ECMO组25例、非ECMO组185例。ECMO组心脏骤停史更多(76.0% vs 53.5%,P=0.001)。胸部器官恢复率ECMO组显著更低(心脏4.2% vs 47.6%;肺4.2% vs 47.0%;均P<0.001),而肝脏(75.0% vs 84.3%,P=0.586)和肾脏恢复率相当。受者生存各器官类型可比,肝移植ECMO来源器官晚期生存概率更高(log-rank P=0.02),但事件数少需谨慎解读。
要点
- ECMO支持的脑死亡供者腹部器官(肝、肾)恢复率与传统供者相当,可考虑用于扩大供者池。
- ECMO组胸部器官(心、肺)恢复率显著降低(均约4.2% vs 约47%,P<0.001),主要归因于基础心肺病变。
- ECMO组供者心脏骤停史比例更高(76.0% vs 53.5%,P=0.001),提示该群体若无体外支持可能无法存活至脑死亡判定。
- 肝移植受者中ECMO来源器官晚期生存概率更高(log-rank P=0.02),但事件数少,仅为假设生成性发现。
- 研究为小样本回顾性设计,结论需更大前瞻性研究确认。
适用人群与场景
- 两中心连续脑死亡器官供者,2012年1月至2025年6月,按供者获取前是否接受ECMO分层(ECMO组25例,非ECMO组185例)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:两中心回顾性队列研究,样本量210例供者(ECMO n=25,非ECMO n=185)。
- 主要终点:器官特异性恢复率及每供者获取器官数;胸部器官恢复率ECMO组显著更低(心脏4.2% vs 47.6%;肺4.2% vs 47.0%;均P<0.001),归因于基础心肺病变。
- 腹部器官恢复率相当:肝脏75.0% vs 84.3%(P=0.586);右肾87.5% vs 89.7%(P=0.845);左肾87.5% vs 91.4%(P=0.649)。
- 受者生存:各器官类型可比;肝移植中ECMO来源器官晚期生存概率更高(log-rank P=0.02),但事件数少需谨慎。
- 基线:ECMO组心脏骤停史更多(76.0% vs 53.5%,P=0.001)。
证据类型、等级与局限
- 证据类型:回顾性队列研究(两中心)。
- 局限:样本量小(ECMO组仅25例)、回顾性设计、事件数少,结论为探索性,需更大前瞻性研究确认。
对床旁实践的改变
- 对于ECMO支持的脑死亡供者,可积极评估腹部器官(肝、肾)用于移植,因恢复率与传统供者相当。
- 胸部器官(心、肺)从ECMO支持供者中获取率低,需结合基础心肺病变谨慎评估。
- ECMO支持供者常有心跳骤停史,不应仅因此排除供者资格,但需个体化评估。
- 肝移植受者使用ECMO来源器官的晚期生存信号需进一步验证,不能作为常规推荐依据。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Organ shortages remain a critical global challenge, and extracorporeal membrane oxygenation (ECMO) has emerged as a potential strategy to preserve organ perfusion and expand the donation after brain death (DBD) donor pool. In regions where donation after circulatory death (DCD) is not legally permitted, maximizing DBD donor utilization carries particular clinical and policy importance. However, evidence regarding organ-specific recovery rates and post-transplant graft outcomes in ECMO-supported DBD donors remains limited and heterogeneous.
METHODS: We conducted a two-center retrospective cohort study of all consecutive brain-dead organ donors managed at two tertiary referral centers between January 2012 and June 2025. Donors were stratified by ECMO exposure prior to organ procurement. Primary outcomes were organ-specific recovery rates and the number of organs recovered per donor. Kaplan-Meier analysis with log-rank testing was used to evaluate post-transplant recipient survival stratified by donor ECMO exposure and organ type.
RESULTS: Of 210 donors (ECMO n=25, non-ECMO n=185), baseline demographics and cause of brain death were broadly comparable, although ECMO donors more frequently had antecedent cardiac arrest (76.0% vs 53.5%, P=0.001), reflecting a population that would likely not have survived to brain death determination without extracorporeal support. Thoracic organ recovery was markedly lower in the ECMO group (heart 4.2% vs 47.6%; lung 4.2% vs 47.0%; both P<0.001), attributable primarily to underlying cardiopulmonary pathology. Abdominal organ recovery was preserved, with comparable rates for liver (75.0% vs 84.3%, P=0.586) and kidneys (right 87.5% vs 89.7%, P=0.845; left 87.5% vs 91.4%, P=0.649). Recipient survival was comparable across organ types; for liver grafts, ECMO-derived organs maintained higher survival probability at late follow-up (log-rank P=0.02), a hypothesis-generating finding that should be interpreted with caution given the small number of events.
CONCLUSIONS: ECMO-supported donors can preserve abdominal organ viability and achieve post-transplant recipient survival comparable to conventional DBD donors, although these findings are exploratory given the small sample size and retrospective design. Whether structured ECMO use represents a meaningful strategy for donor pool expansion, particularly in settings where DCD is unavailable, warrants confirmation in larger prospective studies.
参考来源
- Chung J, Ko RE, Cha S, et al. Utilization and outcomes of organs from ECMO-supported brain-dead donors: two-center experience. J Intensive Care. 2026. PMID: 42698110. doi:10.1186/s40560-026-00933-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。